ClinicalTrials.gg
CompletedNCT02275156Updated Nov 7, 2022Results posted

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

A Phase 1 interventional study of Evolocumab in Hyperlipidemia and Mixed Dyslipidemia, sponsored by Amgen. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-11-07.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.

Enrollment
19th of 21
18 · median 307
Started
2014
with 1 other
Phase 1
2 of 21
none open now
Registered
13th of 21
by date
Lead sponsor
16 of 21
Amgen

Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 19th largest by enrollment, is one of 2 that started in 2014, is one of 2 in phase 1, and was the 13th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing evolocumab in Hyperlipidemias as a file.
02

Study summary

The primary objective of this study was to evaluate the pharmacokinetics of evolocumab after a single 140 mg subcutaneous (SC) dose in aduts with normal renal function or severe renal impairment or end-stage renal disease (ESRD) receiving hemodialysis.

03

Conditions studied

  • Hyperlipidemia
  • Mixed Dyslipidemia

Keywords

  • Subjects with normal renal function or severe renal impairment (RI) or end stage renal disease (ESRD) receiving hemodialysis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of ≥ 18 and ≤ 35 kg/m² at screening.
  • Subjects will have low-density lipoprotein cholesterol (LDL-C) of 70-190 mg/dL (inclusive) and on statin therapy.
  • Other inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Subject with current or prior history of statin intolerance
  • Subject has previously received Evolocumab (AMG 145) or any other therapy directed against PCSK9
  • Known substance abuse (eg, alcohol, licit or illicit drugs) within 12 months of day -1
  • Testing positive for alcohol and/or drugs-of-abuse at screening, day -1, or day 1 (alcohol only)
  • History of or allergic reaction to mammalian-derived drug preparations
  • Known sensitivity to any of the active substances or their to be administered during dosing, eg, carboxymethylcellulose
  • Other exclusion criteria may apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Evolocumab

    Participants received a single 140 mg dose of evolocumab subcutaneously on Day 1.

    Biological: Evolocumab

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection

    Also known as: AMG 145, Repatha

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of Evolocumab

    Serum concentrations of evolocumab were measured by a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) of the assay was 800 ng/mL.

    Time frame: Predose and 4 hours, 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 50 and 57 days postdose

  2. Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last) for Evolocumab

    Time frame: Predose and 4 hours, 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 50 and 57 days postdose

Secondary outcomes

  1. Number of Participants With Adverse Events

    The severity of each adverse event was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: * fatal; * life threatening (places the participant at immediate risk of death); * requires in patient hospitalization or prolongation of existing hospitalization; * results in persistent or significant disability/incapacity; * congenital anomaly/birth defect; * other medically important serious event. The investigator assessed whether each adverse event was possibly related to the study drug.

    Time frame: From the first dose of study drug up until Day 57

  2. Number of Participants With Clinically Relevant Vital Sign or Clinical Laboratory Changes

    The investigator reviewed vital signs and laboratory test results and determined whether an abnormal value in an individual participant represented a clinically significant change from the participant's baseline values.

    Time frame: 57 days

  3. Number of Participants With Anti-evolocumab Antibodies

    Blood samples were tested using an electrochemiluminescence-based bridging immunoassay to detect antibodies capable of binding to evolocumab.

    Time frame: 57 days

  4. Area Under the Effect Curve From Baseline to Day 57 (AUECday1-57) for Low-density Lipoprotein Cholesterol (LDL-C)

    The derived log-transformed AUECday1-57 for direct LDL-C was analyzed using a mixed-effect analysis of variance model. Log-transformed baseline LDL-C was the covariate.

    Time frame: 4 hours, 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 50 and 57 days postdose

  5. Mean Percent Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

    Serum PCSK9 concentrations were determined using a qualified ELISA. The LLOQ of the assay was 15 ng/mL. Log-transformed baseline PCSK9 was included in the model as a covariate and participant as a random effect.

    Time frame: Baseline and 4 hours, 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 50 and 57 days postdose

07

Results

Posted Jan 29, 2016

Participant flow

Eighteen participants were enrolled at 1 center in the United States. The first participant enrolled on 19 August 2014 and the last participant enrolled on 28 October 2014.

Participant flow — Overall Study
MilestoneNormal Renal FunctionSevere Renal ImpairmentEnd Stage Renal Disease
Started666
Completed666
Not completed000

Outcome measures

PrimaryMaximum Observed Serum Concentration (Cmax) of Evolocumab

Serum concentrations of evolocumab were measured by a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) of the assay was 800 ng/mL.

Time frame:
Predose and 4 hours, 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 50 and 57 days postdose
Reported as:
Mean · μg/mL
Maximum Observed Serum Concentration (Cmax) of Evolocumab
μg/mLNormal Renal FunctionSevere Renal ImpairmentEnd Stage Renal Disease
Maximum Observed Serum Concentration (Cmax) of Evolocumab21.3 ± 9.0015.1 ± 8.8611.7 ± 7.20
PrimaryArea Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last) for Evolocumab
Time frame:
Predose and 4 hours, 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 50 and 57 days postdose
Reported as:
Mean · day*μg/mL
Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last) for Evolocumab
day*μg/mLNormal Renal FunctionSevere Renal ImpairmentEnd Stage Renal Disease
Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last) for Evolocumab185 ± 92.5141 ± 109102 ± 80.1
SecondaryNumber of Participants With Adverse Events

The severity of each adverse event was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: * fatal; * life threatening (places the participant at immediate risk of death); * requires in patient hospitalization or prolongation of existing hospitalization; * results in persistent or significant disability/incapacity; * congenital anomaly/birth defect; * other medically important serious event. The investigator assessed whether each adverse event was possibly related to the study drug.

Time frame:
From the first dose of study drug up until Day 57
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsNormal Renal FunctionSevere Renal ImpairmentEnd Stage Renal Disease
Any adverse event112
Grade ≥ 2110
Grade ≥ 3010
Grade ≥ 4000
Serious adverse events010
Leading to discontinuation of study drug000
Leading to discontinuation from study000
Fatal adverse events000
Treatment-related adverse events000
SecondaryNumber of Participants With Clinically Relevant Vital Sign or Clinical Laboratory Changes

The investigator reviewed vital signs and laboratory test results and determined whether an abnormal value in an individual participant represented a clinically significant change from the participant's baseline values.

Time frame:
57 days
Reported as:
Number · participants
Number of Participants With Clinically Relevant Vital Sign or Clinical Laboratory Changes
participantsNormal Renal FunctionSevere Renal ImpairmentEnd Stage Renal Disease
Number of Participants With Clinically Relevant Vital Sign or Clinical Laboratory Changes000
SecondaryNumber of Participants With Anti-evolocumab Antibodies

Blood samples were tested using an electrochemiluminescence-based bridging immunoassay to detect antibodies capable of binding to evolocumab.

Time frame:
57 days
Reported as:
Number · participants
Number of Participants With Anti-evolocumab Antibodies
participantsNormal Renal FunctionSevere Renal ImpairmentEnd Stage Renal Disease
Number of Participants With Anti-evolocumab Antibodies000
SecondaryArea Under the Effect Curve From Baseline to Day 57 (AUECday1-57) for Low-density Lipoprotein Cholesterol (LDL-C)

The derived log-transformed AUECday1-57 for direct LDL-C was analyzed using a mixed-effect analysis of variance model. Log-transformed baseline LDL-C was the covariate.

Time frame:
4 hours, 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 50 and 57 days postdose
Reported as:
Geometric mean · mg/dL*day
Area Under the Effect Curve From Baseline to Day 57 (AUECday1-57) for Low-density Lipoprotein Cholesterol (LDL-C)
mg/dL*dayNormal Renal FunctionSevere Renal ImpairmentEnd Stage Renal Disease
Area Under the Effect Curve From Baseline to Day 57 (AUECday1-57) for Low-density Lipoprotein Cholesterol (LDL-C)4438.6 (3873.3 to 5086.5)4087.5 (3555.5 to 4699.1)4620.2 (4050.8 to 5269.6)
SecondaryMean Percent Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Serum PCSK9 concentrations were determined using a qualified ELISA. The LLOQ of the assay was 15 ng/mL. Log-transformed baseline PCSK9 was included in the model as a covariate and participant as a random effect.

Time frame:
Baseline and 4 hours, 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 50 and 57 days postdose
Reported as:
Geometric mean · percent change
Mean Percent Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
percent changeNormal Renal FunctionSevere Renal ImpairmentEnd Stage Renal Disease
Day 1, Hour 4-91.69 (-94.66 to -87.09)-79.20 (-86.63 to -67.64)-72.95 (-82.59 to -57.97)
Day 2-96.67 (-97.86 to -94.83)-95.87 (-97.34 to -93.57)-94.41 (-96.40 to -91.31)
Day 3-96.67 (-97.86 to -94.83)-96.33 (-97.64 to -94.29)-95.58 (-97.16 to -93.14)
Day 4-96.67 (-97.86 to -94.83)-96.33 (-97.64 to -94.29)-96.53 (-97.77 to -94.61)
Day 6-96.67 (-97.86 to -94.83)-96.33 (-97.64 to -94.29)-95.39 (-97.03 to -92.83)
Day 8-96.67 (-97.86 to -94.83)-96.33 (-97.64 to -94.29)-95.01 (-96.79 to -92.25)
Day 11-96.67 (-97.86 to -94.83)-95.96 (-97.40 to -93.71)-94.69 (-96.58 to -91.75)
Day 15-90.42 (-93.84 to -85.12)-86.41 (-91.26 to -78.86)-82.97 (-89.04 to -73.53)
Day 22-65.84 (-78.02 to -46.40)-57.92 (-72.95 to -34.54)-60.33 (-74.47 to -38.36)
Day 29-49.12 (-67.26 to -20.93)-53.66 (-70.21 to -27.91)-51.88 (-69.03 to -25.23)
Day 43-24.93 (-51.70 to 16.67)-36.30 (-59.05 to -0.92)-42.44 (-62.95 to -10.56)
Day 50-2.88 (-37.51 to 50.95)-26.57 (-52.79 to 14.22)-37.04 (-59.48 to -2.17)
Day 57-1.46 (-36.60 to 53.14)-14.49 (-45.03 to 33.02)-37.74 (-59.93 to -3.25)

Adverse events

Collected over From the first dose of study drug up until Day 57. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Evolocumab 140 mg - Normal Renal Function—0/6 (0%)1/6 (16.7%)
Evolocumab 140 mg - Severe RI—1/6 (16.7%)1/6 (16.7%)
Evolocumab 140 mg - ESRD Requiring Hemodialysis—0/6 (0%)2/6 (33.3%)
Evolocumab 140 mg - Total—1/18 (5.6%)4/18 (22.2%)
Most frequent serious events
Most frequent serious events
EventEvolocumab 140 mg - Normal Renal FunctionEvolocumab 140 mg - Severe RIEvolocumab 140 mg - ESRD Requiring HemodialysisEvolocumab 140 mg - Total
HyperkalaemiaMetabolism and nutrition disorders0/61/60/61/18
Most frequent other events
Most frequent other events
EventEvolocumab 140 mg - Normal Renal FunctionEvolocumab 140 mg - Severe RIEvolocumab 140 mg - ESRD Requiring HemodialysisEvolocumab 140 mg - Total
Abdominal painGastrointestinal disorders0/61/60/61/18
VomitingGastrointestinal disorders0/60/61/61/18
Tooth infectionInfections and infestations1/60/60/61/18
ContusionInjury, poisoning and procedural complications0/60/61/61/18
Upper-airway cough syndromeRespiratory, thoracic and mediastinal disorders0/60/61/61/18
DermatitisSkin and subcutaneous tissue disorders1/60/60/61/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Normal Renal FunctionSevere Renal ImpairmentEnd Stage Renal DiseaseTotal
Mean51.2 ± 9.963.3 ± 7.857.0 ± 8.157.2 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Normal Renal FunctionSevere Renal ImpairmentEnd Stage Renal DiseaseTotal
Female2237
Male44311
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Normal Renal FunctionSevere Renal ImpairmentEnd Stage Renal DiseaseTotal
Black (or African American)1146
White55212
08

Study locations

1 site
  • Research Site
    Denver, Colorado 80230, United States
09

References and documents

Publications

  • Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. PubMed 29353350 ↗
  • Lee E, Gibbs JP, Emery MG, Block G, Wasserman SM, Hamilton L, Kasichayanula S, Hanafin P, Somaratne R, Egbuna O. Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety. Clin Pharmacol Drug Dev. 2019 Apr;8(3):281-289. doi: 10.1002/cpdd.650. Epub 2019 Jan 24. PubMed 30676701 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Dec 2014, 4 months.

Results were first posted in Jan 2016, 1 year 1 month after primary completion.

Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 4 months is above that.

Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2014
First posted
Oct 27, 2014
StartActual
Aug 19, 2014
Primary completionActual
Dec 19, 2014
CompletionActual
Dec 19, 2014
Results first posted
Jan 29, 2016
Last update
Nov 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02275156
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 27, 2014
Start date
Aug 19, 2014
Primary completion
Dec 19, 2014
Completion
Dec 19, 2014
Results posted
Jan 29, 2016
Last update
Nov 7, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion